Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy
The VTE risk of relugolix-CT appears lower than that of traditional combined oral contraceptives. Nonetheless, patient selection is essential, particularly for those with thrombotic risk factors. Continued real-world surveillance is crucial to refining its safety profile in clinical practice.
Authors
- Lorraine Maitrot‐Mantelet (ORCID: https://orcid.org/0000-0001-9449-1696)
- Philippe Descamps (ORCID: https://orcid.org/0000-0002-4280-3237)
- Marie Didembourg (ORCID: https://orcid.org/0000-0002-9170-0314)
- Charles Chapron (ORCID: https://orcid.org/0000-0003-2578-3163)
- Nathalie Chabbert‐Buffet (ORCID: https://orcid.org/0000-0002-6525-4154)
- Jonathan Douxfils (ORCID: https://orcid.org/0000-0002-7644-5298)
- Florence Trémollières
Institutions
- University of Namur (BE)
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Comagine Health (US)
- Institut thématique Immunologie, inflammation, infectiologie et microbiologie (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Centre de Recherche sur l'Inflammation (FR)
- Institut Cochin (FR)
- Hôpital Paule de Viguier (FR)
- Hôpital Tenon (FR)
- Université d'Angers (FR)
Publication Details
- Journal
- Journal of the Endocrine Society
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1210/jendso/bvaf190
- Citations
- 1
- Primary Topic
- Reproductive Health and Contraception
- Type
- article
- Field-Weighted Citation Impact
- 1.88